Biren Amin
Stock Analyst at Piper Sandler
(3.35)
# 937
Out of 5,090 analysts
66
Total ratings
52.54%
Success rate
3.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Initiates: Overweight | $7 | $2.27 | +208.37% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $32.88 | +45.99% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $22.26 | -28.12% | 12 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $93 → $98 | $73.64 | +33.08% | 4 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $26.72 | +150.75% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $12.58 | +146.42% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $80.38 | +18.19% | 2 | Sep 25, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $2.92 | +105.48% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $1.05 | +280.95% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $5.77 | +194.63% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $1.43 | +389.51% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $29.91 | +27.05% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.53 | +117.00% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $38.55 | +84.18% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $10.24 | +241.80% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $19.76 | +6.28% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $69.56 | +65.32% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $23.63 | +35.42% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.93 | -23.66% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.39 | +4,935.97% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.82 | +6,090.82% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $4.70 | +410.64% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.05 | +573.27% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.90 | +55,455.56% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $10.18 | +37.52% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $718.36 | -3.81% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $3.95 | +153.16% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $44.41 | +127.43% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $155.51 | -55.63% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $455.48 | -65.97% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $3.84 | +3,441.67% | 4 | Mar 6, 2017 |
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $2.27
Upside: +208.37%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $32.88
Upside: +45.99%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $22.26
Upside: -28.12%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $73.64
Upside: +33.08%
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $26.72
Upside: +150.75%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $12.58
Upside: +146.42%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $80.38
Upside: +18.19%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $2.92
Upside: +105.48%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $1.05
Upside: +280.95%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.77
Upside: +194.63%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.43
Upside: +389.51%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $29.91
Upside: +27.05%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.53
Upside: +117.00%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $38.55
Upside: +84.18%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $10.24
Upside: +241.80%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $19.76
Upside: +6.28%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $69.56
Upside: +65.32%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $23.63
Upside: +35.42%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.93
Upside: -23.66%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.39
Upside: +4,935.97%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.82
Upside: +6,090.82%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $4.70
Upside: +410.64%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $5.05
Upside: +573.27%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.90
Upside: +55,455.56%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $10.18
Upside: +37.52%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $718.36
Upside: -3.81%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $3.95
Upside: +153.16%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $44.41
Upside: +127.43%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $155.51
Upside: -55.63%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $455.48
Upside: -65.97%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $3.84
Upside: +3,441.67%